News

April 23, 2018April 23, 2018

St. Baldrick’s Foundation Helps Researchers ‘Stand Up To Cancer’ with $8M Gift

News

The St. Baldrick’s Foundation Pediatric Cancer Dream Team, a joint effort with the Stand Up To Cancer (SU2C) fundraising organization, will continue to develop new immunotherapy approaches to high-risk childhood ... Read more

April 20, 2018April 20, 2018

SD-101 and Keytruda Combo Fights Head and Neck Tumors, Trial Shows

News

A combination of Dynavax Technologies’ immunotherapy SD-101 and Keytruda triggered tumor-fighting responses in a third of patients with an advanced head and neck cancer, a Phase 1b/2 clinical trial showed. The response rate was double the 15 percent ... Read more

April 19, 2018April 19, 2018

FDA Approves Opdivo-Yervoy Combo for Advanced Kidney Cancer

News

The U.S. Food and Drug Administration has approved a combination of Opdivo (nivolumab) and Yervoy (ipilimumab) for previously untreated patients with advanced renal cell carcinoma (RCC), Bristol-Myers Squibb (BMS) announced. The approval makes the ... Read more

April 18, 2018April 18, 2018

European Partnership Aims to Better Understand and Predict Immunotherapy Response

News

Better predicting and monitoring immune-related adverse events in cancer patients being treated with immune checkpoint inhibitors is the goal of a partnership between Institut Gustave-Roussy, a leading cancer center based near ... Read more

April 17, 2018

Immunotherapy Combo Boosts Survival in Mouse Models of Mesothelioma, Study Finds

News

A combination of two immunotherapies — VIC-008 and Mozobil (plerixafor, or AMD3100) — suppresses mesothelioma growth and prolongs survival, suggesting a potential therapy for this type of cancer, a mouse ... Read more

April 16, 2018April 16, 2018

First Stage of Bemcentinib-Keytruda Phase 2 Trial for Lung Cancer Completes Patient Enrollment

News

The first part of a Phase 2 trial investigating the AXL inhibitor bemcentinib in combination with Keytruda (pembrolizumab) in advanced non-small cell lung cancer (NSCLC) patients has completed enrollment of the planned 22 ... Read more

April 13, 2018April 13, 2018

Keytruda Beats Chemo at Increasing NSCLC Patients’ Survival, Phase 3 Trial Shows

News

Non-small cell lung cancer (NSCLC) patients with PD-L1 protein in their tumors lived significantly longer when treated with the immunotherapy Keytruda (pembrolizumab) than standard platinum-based chemotherapy, a Phase 3 clinical trial ... Read more

April 12, 2018April 12, 2018

Society of Interventional Oncology and BTG Award Five Cancer Research Grants

News

The Society of Interventional Oncology (SIO) and the therapy development company BTG have chosen five winners of this year’s Immuno-Oncology/Interventional Oncology research grants. They founded the program in 2017 to fund cutting-edge ... Read more

April 11, 2018April 11, 2018

Keytruda-Epacadostat Combo Fails Primary Goal in Phase 3 Trial for Melanoma, Companies Announce

News

A Phase 3 clinical trial evaluating a combination of Keytruda and epacadostat in metastatic melanoma patients will be stopped after the combo failed the study’s first primary goal, Incyte Corporation and Merck announced. Keytruda (pembrolizumab), ... Read more

April 10, 2018

Newly Developed Molecule Boosts Anti-cancer Immunity, Mouse Study Shows

News

A new version of a known molecule is highly effective in stimulating pro-inflammatory and anti-tumor responses in humans, a recent mouse study revealed. These findings, along with the technology used in ... Read more